Breaking News

Akorn Acquires Ophthalmics from Merck

November 15, 2013

Signs two-year supply agreement for AzaSite, COSOPT and COSOPT PF

Akorn, Inc. has acquired the U.S. rights to three branded ophthalmic products, AzaSite, COSOPT and COSOPT PF, from Merck for $52.8 million in cash. In addition, Akorn has signed a two-year supply agreement with Merck and a transition services agreement. Akorn plans to ship COSOPT and COSOPT PF immediately upon closing and expects to begin shipping AzaSite in 1Q14.
"We are excited to announce this transaction which will further expand Akorn's position as a leader in U.S. ophthalmology products," said Raj Rai, chief executive officer, Akorn. "The addition of these branded products to Akorn's portfolio strengthens our business and leverages our existing ophthalmic sales force and physician relationships."
"The decision to divest a portion of our ophthalmics business in the U.S. is part of our ongoing strategy to sharpen our commercial focus and improve our operational effectiveness," said Jay Galeota, president, Hospital and Specialty Care at Merck. "This transaction provides products that complement Akorn's portfolio and is designed to ensure continued access for physicians and patients to these medicines in the U.S."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important